Regeneron’s blood cancer therapy faces setback as FDA raises trial concerns
Regeneron Pharmaceuticals said the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma, raising concerns over the progress of ongoing confirmatory trials.